Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Buchwald

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Steroids|November 21, 2007
Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp modelPeter Buchwald
Expert Opinion on Drug Discovery|March 15, 2013
Computer-aided retrometabolic drug design: soft drugsPeter Buchwald
Frontiers in Pharmacology|June 28, 2019
A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy DataPeter Buchwald
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2020
Soft drugs: design principles, success stories, and future perspectivesPeter Buchwald
Mathematical Biosciences|October 10, 2006
A general bilinear model to describe growth or decline time profilesPeter Buchwald
Theoretical Biology & Medical Modelling|April 18, 2009
FEM-based oxygen consumption and cell viability models for avascular pancreatic isletsPeter Buchwald
Frontiers in Pharmacology|April 23, 2025
Quantification of signal amplification for receptors: the <i>K</i> <sub>d</sub>/EC<sub>50</sub> ratio of full agonists as a gain parameterPeter Buchwald
Journal of Medicinal Chemistry|February 3, 2006
Soft quaternary anticholinergics: comprehensive quantitative structure-activity relationship (QSAR) with a linearized biexponential (LinBiExp) modelPeter Buchwald, Nicholas Bodor
Methods in Molecular Biology (Clifton, N.J.)|May 17, 2002
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolitesNicholas Bodor, Peter Buchwald
Current Drug Targets|February 24, 2015
TNF superfamily protein-protein interactions: feasibility of small- molecule modulationYun Song, Peter Buchwald
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Steroids|November 21, 2007
Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp modelPeter Buchwald
Expert Opinion on Drug Discovery|March 15, 2013
Computer-aided retrometabolic drug design: soft drugsPeter Buchwald
Frontiers in Pharmacology|June 28, 2019
A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy DataPeter Buchwald
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2020
Soft drugs: design principles, success stories, and future perspectivesPeter Buchwald
Mathematical Biosciences|October 10, 2006
A general bilinear model to describe growth or decline time profilesPeter Buchwald
Theoretical Biology & Medical Modelling|April 18, 2009
FEM-based oxygen consumption and cell viability models for avascular pancreatic isletsPeter Buchwald
Frontiers in Pharmacology|April 23, 2025
Quantification of signal amplification for receptors: the <i>K</i> <sub>d</sub>/EC<sub>50</sub> ratio of full agonists as a gain parameterPeter Buchwald
Journal of Medicinal Chemistry|February 3, 2006
Soft quaternary anticholinergics: comprehensive quantitative structure-activity relationship (QSAR) with a linearized biexponential (LinBiExp) modelPeter Buchwald, Nicholas Bodor
Methods in Molecular Biology (Clifton, N.J.)|May 17, 2002
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolitesNicholas Bodor, Peter Buchwald
Current Drug Targets|February 24, 2015
TNF superfamily protein-protein interactions: feasibility of small- molecule modulationYun Song, Peter Buchwald
Pageof 10